Our results revealed that EGFR and HER2 FolTAC-dual v1.0 and Trastuzumab specifically inhibit SKBR3-WT cancer cells while sparing HFF-1 cells (Fig. 4d, e). This evidence concerns the gene ERBB2 and cancer.